OptimizeRx (NASDAQ:OPRX) Lowered to Hold Rating by Zacks Research

Zacks Research lowered shares of OptimizeRx (NASDAQ:OPRX) from a strong-buy rating to a hold rating in a report issued on Monday,Zacks.com reports.

A number of other equities analysts also recently commented on the stock. Citizens Jmp lifted their target price on shares of OptimizeRx from $23.00 to $24.00 and gave the stock a “market outperform” rating in a research note on Friday, November 7th. JMP Securities lifted their price target on shares of OptimizeRx from $20.00 to $23.00 and gave the company a “market outperform” rating in a research report on Friday, October 10th. Weiss Ratings restated a “sell (d+)” rating on shares of OptimizeRx in a report on Monday. Wall Street Zen raised OptimizeRx from a “buy” rating to a “strong-buy” rating in a research report on Sunday. Finally, UBS Group set a $23.00 price target on OptimizeRx in a research report on Friday, October 10th. Seven equities research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, OptimizeRx presently has a consensus rating of “Moderate Buy” and an average target price of $16.88.

OptimizeRx Stock Performance

OPRX opened at $13.30 on Monday. The stock has a market cap of $247.82 million, a P/E ratio of 32.95 and a beta of 1.10. The company has a debt-to-equity ratio of 0.20, a current ratio of 3.05 and a quick ratio of 3.05. The firm has a fifty day moving average price of $16.84 and a 200 day moving average price of $15.97. OptimizeRx has a 1 year low of $3.99 and a 1 year high of $22.25.

OptimizeRx (NASDAQ:OPRX) last announced its earnings results on Thursday, November 6th. The company reported $0.20 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.03 by $0.17. OptimizeRx had a return on equity of 6.37% and a net margin of 0.03%.The firm had revenue of $26.07 million for the quarter, compared to analyst estimates of $23.83 million. Equities research analysts anticipate that OptimizeRx will post -0.33 earnings per share for the current year.

Insiders Place Their Bets

In related news, CEO Stephen L. Silvestro sold 1,620 shares of OptimizeRx stock in a transaction that occurred on Friday, October 3rd. The shares were sold at an average price of $18.75, for a total value of $30,375.00. Following the completion of the transaction, the chief executive officer owned 188,916 shares in the company, valued at $3,542,175. The trade was a 0.85% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. 5.60% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On OptimizeRx

A number of institutional investors and hedge funds have recently modified their holdings of OPRX. Los Angeles Capital Management LLC acquired a new position in OptimizeRx in the second quarter valued at $349,000. Rhumbline Advisers lifted its position in OptimizeRx by 10.5% during the 1st quarter. Rhumbline Advisers now owns 27,785 shares of the company’s stock worth $241,000 after acquiring an additional 2,636 shares during the period. Connor Clark & Lunn Investment Management Ltd. acquired a new stake in OptimizeRx during the 2nd quarter worth approximately $418,000. P.A.W. Capital Corp acquired a new position in shares of OptimizeRx in the second quarter valued at approximately $675,000. Finally, Parkman Healthcare Partners LLC acquired a new stake in shares of OptimizeRx during the first quarter worth $4,114,000. Institutional investors and hedge funds own 76.47% of the company’s stock.

OptimizeRx Company Profile

OptimizeRx Corporation, a digital health technology company, enables care-focused engagement between life sciences organizations, healthcare providers, and patients at critical junctures throughout the patient care journey. It offers various tech-enabled marketing solutions through its Artificial Intelligence-generated Dynamic Audience and Activation Platform, which enables customers to execute traditional marketing campaigns on its proprietary digital point-of-care network, as well as dynamic marketing campaigns that optimize audiences in real time to increase the value of treatment information for healthcare professionals and patients in response to clinical care events.